InSilico Medicine Cayman TopCo

InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is designed to enhance the quality and productivity of pharmaceutical research. The company has a strategic partnership with Liquid AI for the development of lightweight AI foundation models for drug discovery; and has a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. to identify novel therapeutic targets with high drug development potential for challenging gynecological conditions, including endometriosis, uterine fibroids, and adenomyosis. The company was founded in 2014 and is based in New Territories, Hong Kong.